Skip to main content

Table 1 Clinical characteristics of the sample

From: Outcome measures and treatment effectiveness in late onset myasthenia gravis

Type of MG (n° pts) OCULAR (36) EOMG (40) LOMG (72) THYMOMA (25) SN (21) ANTI-MUSK (14) Total (208)
sex Female/male 14 /22 36 /4 17 /55 15 /10 12 /9 10 /4 104 /104
Average age (years) 68,3 ± 10.9 44,2 ± 10,7 73,5 ± 8,5 59,4 ± 14,4 58,3 ± 10,9 57,4 ± 8,9 62,6 ± 15,0
Average age at onset (years) 60,8 ± 15,3 28,9 ± 11,5 66,8,1 ± 9,3 45,0 ± 16,3 48,2 ± 16,5 44,8 ± 16,8 52,3 ± 19,4
Disease duration 7,4 ± 7,7 16,0 ± 11,3 6,7 ± 4,0 14,4 ± 9,4 10,1 ± 9,2 12,6 ± 12,5 10,3 ± 9,1
Severity at Onset (MGFA) I 36 1 (2,5%) 23 (31,9%) 2 10 0 72 (34,6%)
IIA/IIB 0 11 (27,5%)/14 (35%) 11 (15,3%)/26 (36,1%) 5/12 5/12 2 /9 34 (16,3%)/65 (31,2%)
IIIA/IIIB 0 1 (2,5%)/11 (27,5%) 2 (2,8%)/10 (13,9%) 1/5 1/5 1/1 6 (2,9%)/25 (12,1%)
IVA/IVB 0 1 (2,5%)/1 (2,5%) 0 0 0 0/1 1 (0,5%)/2 (1%)
Worst severity during the course of the disease (MGFA) I 36 0 0 0 0 0 36 (17,3%)
IIA/IIB 0 5 (12,5%)/11 (27,5%) 8 (11,1%)/25 (34,7%) 4/4 7/7 1/4 25 (12,1%)/51 (24,5)
IIIA/IIIB 0 2 (5%)/13 (32,5%) 3 (4,2%)/24 (33,3%) 2/11 1/5 0/4 8 (3,8%)/57 (27,4%)
IVA/IVB 0 2 (5%)/3 (7,5%) 2 (2,8%)/7 (9,7%) 0/3 0/1 0/3 4 (1,9%)/17 (8,2%)
V 0 4 (10%) 3 (4,2%) 1 0 2 10 (4,8%)
thymic hyperplasia (histology/thymectomized) 2/3 34/34 4/4 0/25 4/5 0/1 44/ 72
N. of comorbidity 0 9 (25%) 20 (50%) 7 (9,7%) 8 (32%) 3 (14,3%) 3 (21,4%) 50
1–2 24 (66,7%) 14 (35%) 39 (54,2%) 10 (40%) 17 (80,9%) 9 (64,3%) 113
3–4 3 (8,3%) 6 (15%) 22 (30,6%) 6 (24%) 1 (4,8%) 2 (14,3%) 40
5–6    4 (5,6%) 1 (4%)    5
  1. Abbreviations: F Females, M Males, T Total, EOMG Early onset myasthenia gravis, LOMG Late onset myasthenia gravis, MUSK Muscle specific tyrosine kinase, SN Double seronegative